Notification of buy-back - ACL
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Australian Clinical Labs Ltd has announced a buy-back of its ordinary fully paid securities on the market. The maximum number of securities proposed to be bought back is specified, although the exact price is not yet known. The buy-back is set to commence in mid-September and is expected to conclude in mid-September of the following year. The company retains the right to suspend or terminate the buy-back based on various factors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Australian Clinical Labs Ltd on 6ix
In the deck
Story so far
Earlier from Australian Clinical Labs
- FY24 financial results investor presentation
- Appendix 4E and FY24 financial statements
- FY24 Trading Update
- Appendix 4D and 1H24 financial reports
- 1H24 investor presentation
Later from Australian Clinical Labs
- Sale of Crescent Capital shareholding
- 1H25 financial results investor presentation
- Appendix 4D and 1H25 financial statements
- Response to ASX Aware Letter
- FY25 Results Presentation
Follow Australian Clinical Labs into a list and get an email when it puts out news.
Follow Australian Clinical Labs